Comparative effectiveness of dimethyl fumarate in multiple sclerosis.

Pauline Bosco-LevyMarc DebouverieBruno BrochetFrancis GuilleminCéline LouapreElisabeth MaillartOlivier HeinzlefSéverine LignotPauline DiezAbdelilah AbouelfathRégis LassallePatrick BlinCécile Droz-Perroteau

Published in: British journal of clinical pharmacology (2021)

DMF is associated with lower risk of treated relapse for patients with RRMS than other first-line RRMS agents (TERI and IIM).

Keyphrases

multiple sclerosis
white matter
free survival
newly diagnosed